CHICAGO – Several patients with acute myeloid leukemia (AML), who were treated with SENTI-202, a first-in-class chimeric antigen receptor...
CHICAGO – Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA...
CHICAGO – PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients...
CHICAGO – Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced...
CHICAGO – Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients...
CHICAGO – The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented...
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...